查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1495980

全球尿液检查市场－2024年至2029年预测

Global Urinalysis Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 135 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计预测期内尿液检查市场将以5.86%的年复合成长率成长，市场规模预计将从2022年的30.15亿美元增至2029年的44.89亿美元。

尿液检查是尿液检查，用于诊断和治疗多种疾病，包括尿道感染(UTI)、肾臟疾病和糖尿病。尿液检查可评估尿液的外观、浓度和含量。如果您的尿液观察异常，则怀疑患有某种疾病。 2021 年 9 月，Eurek Aert 报告称，希望之城附属机构转化基因组学研究所 (TGen) 正在利用尿液检查来分析尿液中的小链游离 DNA，并找到了一种识别方法。现已开发出多种非侵入式自动化尿液分析仪，以提供快速、准确的检测结果。

尿道结石、糖尿病、肾臟和肝臟疾病盛行率的增加、老年人口的增加以及与老龄化相关的疾病的增加正在推动市场扩张。医院的加护病房和内外科病房的尿道结石、肾臟病和糖尿病等疾病的盛行率可能较高。根据国家生物技术资讯中心的数据，三分之一的女性会在 24 岁时患上尿道结石，一半的女性会在 32 岁时患上尿结石。

此外，根据国际糖尿病联盟的数据，2019年约有4.63亿年龄在20岁至79岁之间的人患有糖尿病，预计到2045年这一数字将增加至7亿。此外，根据美国国家肾臟基金会的数据，慢性肾臟病(CKD) 影响着全球 10% 的人口，每年导致数百万人死亡。

然而，严格的法律规范和不利的报销条款可能会阻碍未来几年的市场扩张。

市场驱动因素：

  • 预计老年人口的增加和与老龄化相关的疾病将扩大尿液检查市场。

已开发国家和新兴国家老年人口的增加将推动尿液检查市场的成长。据世界卫生组织 (WHO) 称，到 2020 年，60 岁以上的成年人将超过 5 岁以下的儿童。随着老年人口的增加，糖尿病、肾臟和肝臟疾病等与老龄化相关的疾病的盛行率预计将急剧上升。

根据国际糖尿病组织的数据，65 岁以上的人中有五分之一患有糖尿病。由于对此类疾病的诊断和治疗的增加，用于肌酸酐、白蛋白、葡萄糖、酮体和胆红素等检查的处方正在增加，这对用于执行这些检查的尿液检查有利。

市场限制因素：

  • 不利的报销条款可能会阻碍尿液检查市场的发展。

市场成长的一个障碍是翻新设备的可用性，这些设备以较低的成本提供与新设备相同的功能。一些最终客户（主要是中小型实验室）正在选择经济高效的再生设备。尤其是在市场对价格敏感的新兴国家，更喜欢具有类似功能的更便宜的设备。这可能会限制销售品牌分析设备的公司的收益并抑制市场成长。

北美地区预计有很大的市场。

由于人口老化和慢性肾臟病的高盛行率，北美市场预计将占据重要的市场地位。肾衰竭、高血压和糖尿病都与 CKD 有关。根据美国国家肾臟基金会的数据，每年死于 CKD 的人数多于死于乳癌或摄护腺癌的人数。肾臟疾病是美国的首要死因。目前它影响着美国大约 3700 万人。肾臟疾病在老年人中很常见，影响约 15% 的成年人口。

肾臟疾病影响约三分之一的糖尿病患者和大约五分之一的高血压成年人。因此，对 CKD 的准确检测和治疗的需求不断增长，这些因素可能会推动尿液检查的需求。

主要发展

  • 2023 年 12 月 - 西门子 Healthineers 推出了 Atellica UAS 60 分析仪，这是一种用于尿液沉渣分析的数位解决方案。这种自动化工具取代了手动显微镜，可以更快、更准确地审查和报告结果。每个样本产生 15 张高解析度数位影像，并采用自动影像评估模组技术来自动识别颗粒、即时查看模式以可视化运动，以及自动细菌子分类以更轻鬆地识别 CKD 和尿道结石。
  • 2022 年 11 月 - EmeritusDX 和 KDx Diagnostics Inc. 合作开发 URO17，这是一种用于膀胱癌检测的非侵入性尿液检查。 URO17 是一种高灵敏度和高阴性预测值 (NPV) 检测，可确定活动性膀胱癌的状态并改善患者诊断。 EmeritusDX 在美国作为临床实验室开发的测试提供，能够向全国泌尿系统诊所提供 URO17 测试。
  • 2022 年 10 月 - IoMT 医疗科技新兴企业Olive Diagnostics 的创新人工智慧尿液分析仪 Olive KG 获得了欧洲 CE 标誌。该设备是世界上第一款免持、非侵入性、基于人工智慧的光学设备，可安装在任何厕所中，实现被动、无缝尿液分析。它可以测量红血球、蛋白质、亚硝酸盐、pH值、尿量、尿压、尿液颜色、排尿频率等，无需使用者干预即可对患者尿液中的重要参数进行高品质分析。该设备产生受 GDPR 和 HIPPA 要求保护的即时个人资料，这些数据会传输到云端并由您的医生进行处理。
  • 2022 年 9 月 - Sysmex 公司宣布推出一款用于尿液沉渣检测的新产品，全自动尿液颗粒分析仪 (UF-1500)。 UF-1500 继承了 UF-5000 的功能和可操作性，同时更加紧凑。我们提供适合您环境的广泛解决方案，并为中小型设施的尿液检查的合理化和标准化做出贡献。它还可以连接到尿液生化分析仪的传输系统，满足各种客户的需求，包括中小型设施和大型设施的备份系统的要求。

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关利益者的主要利益

第二章调查方法

  • 研究设计
  • 调查过程

第三章执行概述

  • 主要发现

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析
  • 分析师观点

第五章全球尿液检查市场：依产品类型

  • 介绍
  • 装置
    • 市场机会和趋势
    • 成长前景
    • 地理收益
    • 自动尿液分析仪
    • 半自动尿液分析仪
    • 照护现场尿液分析仪
  • 消耗品
    • 市场机会和趋势
    • 成长前景
    • 地理收益
    • 试剂
    • 套件
    • 量油尺
    • 免洗用品

第六章全球尿液检查市场：依测试类型

  • 介绍
  • 尿液生化检测
  • 怀孕及生殖尿液检查
  • 尿沉渣试验

第七章全球尿液检查市场：依应用分类

  • 介绍
  • 尿道感染
  • 糖尿病
  • 肾臟疾病
  • 肝病
  • 怀孕和生育
  • 其他的

第八章全球尿液检查市场：依最终用户分类

  • 介绍
  • 医院/诊所
  • 诊断实验室
  • 研究/学术机构
  • 居家照护

第九章全球尿液检查市场：按地区

  • 介绍
  • 北美洲
  • 南美洲
  • 欧洲
  • 中东/非洲
  • 亚太地区

第十章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞争对手仪表板

第十一章 公司简介

  • ARKRAY, Inc.
  • 77 Elektronika Kft.
  • Siemens Healthineers AG
  • F. Hoffmann-La Roche Ltd.
  • Beckman Coulter, Inc.
  • Abbott Laboratories
  • Sysmex Corporation
  • Neomedica doo
  • Mindray Medical International Limited
  • Analis sa/nv
简介目录
Product Code: KSI061612092

The global urinalysis market is expected to grow at a compound annual growth rate of 5.86% over the forecast period to reach a market size of US$4.489 billion in 2029 from US$3.015 billion in 2022.

Urinalysis is a urine test that is used to diagnose and treat a variety of conditions, including urinary tract infections (UTI), kidney disease, and diabetes. During a urinalysis, the appearance, concentration, and content of urine are all evaluated. Abnormal urine findings may indicate a condition or illness. In September 2021, according to Eurek Aert, the Translational Genomics Research Institute (TGen), a City of Hope affiliate, discovered a method to pinpoint early-stage cancer by utilizing Urinalysis to analyze small strands of cell-free DNA in urine. Various non-invasive urine automated analyzers have been developed to provide rapid and accurate test results.

The increased prevalence of UTIs, diabetes, and kidney and liver disorders, as well as the growing geriatric population and the resulting increase in age-related diseases, are driving market expansion. In hospitals and other critical care units and medical-surgical units, the prevalence of conditions such as UTI, renal disease, and diabetes is likely to be greater. According to the National Centre of Biotechnology Information, one-third of women will have experienced a UTI by the age of 24 and half by the age of 32.

Additionally, according to the International Diabetes Federation, about 463 million individuals between the age of 20-79 years had diabetes in 2019, and this number is expected to grow to 700 million by 2045. Furthermore, according to the National Kidney Foundation, chronic kidney disease (CKD) affects 10% of the world's population, with millions dying each year.

However, the market expansion is likely to be hampered in the coming years by a strict regulatory framework and an unfavorable reimbursement condition.

Market Drivers:

  • Rising geriatric population and age-related diseases are anticipated to increase the global urinalysis market.

The growing geriatric population in developed and developing countries will boost the urinalysis market growth. According to the World Health Organization, the number of adults aged 60 and more will surpass children under the age of five by 2020. The prevalence of age-related diseases such as diabetes and kidney and liver disease is projected to rise dramatically as the geriatric population grows.

According to the International Diabetes Organization, one in every five persons over the age of 65 has diabetes. Prescriptions for tests such as creatinine, albumin, glucose, ketones, and bilirubin, among others, are on the rise as a result of the increased diagnosis and treatment of such disorders, which is benefiting urinalysis, which is used to perform these tests.

Market Restraints:

  • Unfavorable reimbursement conditions could hamper the global urinalysis market.

The availability of refurbished instruments, which provide the same functionality as new equipment at a cheaper cost, poses a barrier to market growth. Several end customers, primarily small and medium-sized laboratories, choose cost-effective reconditioned equipment. Particularly in developing nations, where markets are price-sensitive, inexpensive instruments with equivalent functions are preferred. This is likely to limit the revenue of companies that sell branded analyzers, thus limiting the market growth.

The North American region is projected to have a significant marketplace.

Due to an aging population and a high prevalence of CKD, the North American market is projected to have a significant market position. Kidney failure, high blood pressure, and diabetes are all linked to CKD. According to the National Kidney Foundation, more people die due to CKD than breast cancer and prostate cancer each year. In the United States, kidney disease is a major cause of death. It now affects around 37 million individuals in the US. It is more common in the aging population, affecting around 15% of the adult population.

Kidney disease affects around one in every three individuals with diabetes and one in every five adults with high blood pressure. Hence, there is a growing demand for accurate detection and treatment of CKD, and these factors are likely to drive up demand for urinalysis.

Key Developments:

  • December 2023- Siemens Healthineers introduced the Atellica UAS 60 Analyzer, a digital solution for urine sediment analysis. This automated tool replaces manual microscopy, enabling quicker and more accurate results review and reporting. It generates 15 high-resolution digital images per sample, features auto Image Evaluation Module technology for automatic identification of particles, live-view mode for movement visualization, and automatic bacterial subcategorization for easier identification of CKD and UTI.
  • November 2022- EmeritusDX and KDx Diagnostics Inc. partnered to offer the URO17 non-invasive urine test for bladder cancer detection. URO17 is a highly sensitive and negative predicted value (NPV) test that can determine the status of active bladder cancer and improve patient diagnosis. It is available as a Laboratory Developed Test in the US, allowing EmeritusDX to offer URO17 testing to Urology practices nationwide. The test can rule out patients with micro-hematuria for unnecessary cystoscopy and reduce the work-up.
  • October 2022- Olive Diagnostics, an IoMT MedTech startup, received the European CE Mark for its innovative AI-based urine analysis device, the Olive KG. The device is the world's first hands-free, non-invasive, AI-based optical device for passive and seamless urinalysis mounted on any toilet. It performs high-quality analysis of important parameters in patients' urine without user intervention, measuring red blood cells, proteins, Nitrites, pH levels, volume, pressure, color, and frequency of urination. The device generates real-time personal data, secured according to GDPR and HIPPA requirements, which is sent to the cloud and treated by the treating physician.
  • September 2022- Sysmex Corporation introduced the UF-1500 Fully Automated Urine Particle Analyzer (UF-1500), a new product for urine sediment testing. The UF-1500 inherits the functionality and usability of the UF-5000 model but is downsized. It offers a wider range of solutions tailored to customers' environments and contributes to streamlining and standardization of urine testing at small and medium-sized facilities. The UF-1500 supports connectivity with transportation systems for urine chemistry analyzers, meeting various customer needs, including demand from small and medium-sized facilities and backup systems from large facilities.

Market Segmentation:

By Product Type

  • Instruments
  • Automated Urine Analyzer
  • Semi-automated Urine Analyzer
  • Point-of-Care Urine Analyzer
  • Consumables
  • Reagents
  • Kits
  • Dipsticks
  • Disposables

By Test Type

  • Biochemical Urinalysis
  • Pregnancy & Fertility Urinalysis
  • Sediment Urinalysis

By Application

  • Urinary Tract Infections
  • Diabetes
  • Kidney Diseases
  • Liver Diseases
  • Pregnancy and Fertility
  • Others

By End-User

  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Research & Academic Institutions
  • Home Care Settings

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • South Africa
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL URINALYSIS MARKET BY PRODUCT TYPE

  • 5.1. Introduction
  • 5.2. Instruments
    • 5.2.1. Market Opportunities and Trends
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
    • 5.2.4. Automated Urine Analyzer
    • 5.2.5. Semi-automated Urine Analyzer
    • 5.2.6. Point-of-Care Urine Analyzer
  • 5.3. Consumables
    • 5.3.1. Market Opportunities and Trends
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness
    • 5.3.4. Reagents
    • 5.3.5. Kits
    • 5.3.6. Dipsticks
    • 5.3.7. Disposables

6. GLOBAL URINALYSIS MARKET BY TEST TYPE

  • 6.1. Introduction
  • 6.2. Biochemical Urinalysis
    • 6.2.1. Market Opportunities and Trends
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness
  • 6.3. Pregnancy & Fertility Urinalysis
    • 6.3.1. Market Opportunities and Trends
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness
  • 6.4. Sediment Urinalysis
    • 6.4.1. Market Opportunities and Trends
    • 6.4.2. Growth Prospects
    • 6.4.3. Geographic Lucrativeness

7. GLOBAL URINALYSIS MARKET BY APPLICATION

  • 7.1. Introduction
  • 7.2. Urinary Tract Infections
    • 7.2.1. Market Opportunities and Trends
    • 7.2.2. Growth Prospects
    • 7.2.3. Geographic Lucrativeness
  • 7.3. Diabetes
    • 7.3.1. Market Opportunities and Trends
    • 7.3.2. Growth Prospects
    • 7.3.3. Geographic Lucrativeness
  • 7.4. Kidney Diseases
    • 7.4.1. Market Opportunities and Trends
    • 7.4.2. Growth Prospects
    • 7.4.3. Geographic Lucrativeness
  • 7.5. Liver Diseases
    • 7.5.1. Market Opportunities and Trends
    • 7.5.2. Growth Prospects
    • 7.5.3. Geographic Lucrativeness
  • 7.6. Pregnancy and Fertility
    • 7.6.1. Market Opportunities and Trends
    • 7.6.2. Growth Prospects
    • 7.6.3. Geographic Lucrativeness
  • 7.7. Others
    • 7.7.1. Market Opportunities and Trends
    • 7.7.2. Growth Prospects
    • 7.7.3. Geographic Lucrativeness

8. GLOBAL URINALYSIS MARKET BY END-USER

  • 8.1. Introduction
  • 8.2. Hospitals & Clinics
    • 8.2.1. Market Opportunities and Trends
    • 8.2.2. Growth Prospects
    • 8.2.3. Geographic Lucrativeness
  • 8.3. Diagnostic Laboratories
    • 8.3.1. Market Opportunities and Trends
    • 8.3.2. Growth Prospects
    • 8.3.3. Geographic Lucrativeness
  • 8.4. Research & Academic Institutions
    • 8.4.1. Market Opportunities and Trends
    • 8.4.2. Growth Prospects
    • 8.4.3. Geographic Lucrativeness
  • 8.5. Home Care Settings
    • 8.5.1. Market Opportunities and Trends
    • 8.5.2. Growth Prospects
    • 8.5.3. Geographic Lucrativeness

9. GLOBAL URINALYSIS MARKET BY GEOGRAPHY

  • 9.1. Introduction
  • 9.2. North America
    • 9.2.1. By Product Type
    • 9.2.2. By Test Type
    • 9.2.3. By Application
    • 9.2.4. By End-User
    • 9.2.5. By Country
      • 9.2.5.1. USA
        • 9.2.5.1.1. Market Opportunities and Trends
        • 9.2.5.1.2. Growth Prospects
      • 9.2.5.2. Canada
        • 9.2.5.2.1. Market Opportunities and Trends
        • 9.2.5.2.2. Growth Prospects
      • 9.2.5.3. Mexico
        • 9.2.5.3.1. Market Opportunities and Trends
        • 9.2.5.3.2. Growth Prospects
  • 9.3. South America
    • 9.3.1. By Product Type
    • 9.3.2. By Test Type
    • 9.3.3. By Application
    • 9.3.4. By End-User
    • 9.3.5. By Country
      • 9.3.5.1. Brazil
        • 9.3.5.1.1. Market Opportunities and Trends
        • 9.3.5.1.2. Growth Prospects
      • 9.3.5.2. Argentina
        • 9.3.5.2.1. Market Opportunities and Trends
        • 9.3.5.2.2. Growth Prospects
      • 9.3.5.3. Others
        • 9.3.5.3.1. Market Opportunities and Trends
        • 9.3.5.3.2. Growth Prospects
  • 9.4. Europe
    • 9.4.1. By Product Type
    • 9.4.2. By Test Type
    • 9.4.3. By Application
    • 9.4.4. By End-User
    • 9.4.5. By Country
      • 9.4.5.1. Germany
        • 9.4.5.1.1. Market Opportunities and Trends
        • 9.4.5.1.2. Growth Prospects
      • 9.4.5.2. France
        • 9.4.5.2.1. Market Opportunities and Trends
        • 9.4.5.2.2. Growth Prospects
      • 9.4.5.3. UK
        • 9.4.5.3.1. Market Opportunities and Trends
        • 9.4.5.3.2. Growth Prospects
      • 9.4.5.4. Italy
        • 9.4.5.4.1. Market Opportunities and Trends
        • 9.4.5.4.2. Growth Prospects
      • 9.4.5.5. Spain
        • 9.4.5.5.1. Market Opportunities and Trends
        • 9.4.5.5.2. Growth Prospects
      • 9.4.5.6. Others
        • 9.4.5.6.1. Market Opportunities and Trends
        • 9.4.5.6.2. Growth Prospects
  • 9.5. Middle East and Africa
    • 9.5.1. By Product Type
    • 9.5.2. By Test Type
    • 9.5.3. By Application
    • 9.5.4. By End-User
    • 9.5.5. By Country
      • 9.5.5.1. Saudi Arabia
        • 9.5.5.1.1. Market Opportunities and Trends
        • 9.5.5.1.2. Growth Prospects
      • 9.5.5.2. UAE
        • 9.5.5.2.1. Market Opportunities and Trends
        • 9.5.5.2.2. Growth Prospects
      • 9.5.5.3. South Africa
        • 9.5.5.3.1. Market Opportunities and Trends
        • 9.5.5.3.2. Growth Prospects
      • 9.5.5.4. Others
        • 9.5.5.4.1. Market Opportunities and Trends
        • 9.5.5.4.2. Growth Prospects
  • 9.6. Asia Pacific
    • 9.6.1. By Product Type
    • 9.6.2. By Test Type
    • 9.6.3. By Application
    • 9.6.4. By End-User
    • 9.6.5. By Country
      • 9.6.5.1. China
        • 9.6.5.1.1. Market Opportunities and Trends
        • 9.6.5.1.2. Growth Prospects
      • 9.6.5.2. India
        • 9.6.5.2.1. Market Opportunities and Trends
        • 9.6.5.2.2. Growth Prospects
      • 9.6.5.3. Japan
        • 9.6.5.3.1. Market Opportunities and Trends
        • 9.6.5.3.2. Growth Prospects
      • 9.6.5.4. South Korea
        • 9.6.5.4.1. Market Opportunities and Trends
        • 9.6.5.4.2. Growth Prospects
      • 9.6.5.5. Taiwan
        • 9.6.5.5.1. Market Opportunities and Trends
        • 9.6.5.5.2. Growth Prospects
      • 9.6.5.6. Thailand
        • 9.6.5.6.1. Market Opportunities and Trends
        • 9.6.5.6.2. Growth Prospects
      • 9.6.5.7. Indonesia
        • 9.6.5.7.1. Market Opportunities and Trends
        • 9.6.5.7.2. Growth Prospects
      • 9.6.5.8. Others
        • 9.6.5.8.1. Market Opportunities and Trends
        • 9.6.5.8.2. Growth Prospects

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 10.1. Major Players and Strategy Analysis
  • 10.2. Market Share Analysis
  • 10.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 10.4. Competitive Dashboard

11. COMPANY PROFILES

  • 11.1. ARKRAY, Inc.
  • 11.2. 77 Elektronika Kft.
  • 11.3. Siemens Healthineers AG
  • 11.4. F. Hoffmann-La Roche Ltd.
  • 11.5. Beckman Coulter, Inc.
  • 11.6. Abbott Laboratories
  • 11.7. Sysmex Corporation
  • 11.8. Neomedica d.o.o.
  • 11.9. Mindray Medical International Limited
  • 11.10. Analis sa/nv